<DOC>
	<DOCNO>NCT02707575</DOCNO>
	<brief_summary>The investigator evaluate concentration cytokeratin 8 aqueous humor eye exudative age-related macular degeneration ( AMD ) therapy intravitreal Ranibizumab , identify association visual anatomical outcome treatment .</brief_summary>
	<brief_title>Cytokeratin 8 Level Age-related Macular Degeneration</brief_title>
	<detailed_description>In non-randomized , open-label study , investigator prospectively evaluate 40 patient treatment naive exudative age-related macular degeneration ( AMD ) receive intravitreal ranibizumab injection . A mean volume 0.1 ml aqueous humor sample take time intravitreal injection indicate perform . Cytokeratin 8 level aqueous humor evaluate , association baseline cytokeratin 8 level visual ( best correct visual acuity change ) anatomical ( optical coherence tomography parameter ) Ranibizumab injection investigate .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>1 . Treatmentnaive neovascular AMD patient require intravitreal injection Ranibizumab 2 . A recent onset disease confirm history clinical finding . 3 . Patient require least 50 year age 1 . Myopia refractive error &gt; 3.0 diopter evidence pathologic myopia ( preoperative refractive data use ass pseudophakic eye ) 2 . Any history vitrectomy , antiVEGF therapy , photodynamic therapy ( PDT ) 3 . History cataract surgery within 3 month prior presentation 4 . Evidence endstage AMD subfoveal fibrosis atrophy 5 . Evidence retinal disease include central serous chorioretinopathy neovascularmaculopathies ; glaucoma ; poor imaging data cause medium opacity ; unstable fixation 6 . Patients uncontrolled systemic disease , use immunosuppressive drug , malignant tumor location</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Keratin</keyword>
	<keyword>Ranibizumab</keyword>
</DOC>